Since ruxolitinib is currently the only approved JAK inhibitor for the treatment of MPN but novel and more specific compounds are being developed, the question whether specificity of inhibitors for the JAK1 or JAK2 function (or both) are required for the T-cell function [75] is of utmost importance. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.